RTP Mobile Logo
Recently Available and Emerging Systemic Treatments for Prostate Cancer
Released April 2012

Proceedings from a CME symposium held at the 2012 Genitourinary Cancers Symposium. Featuring perspectives from Drs Tomasz M Beer, Christopher J Logothetis, William K Oh, A Oliver Sartor and Mary-Ellen Taplin. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.


    Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and accounts for almost 30% of all newly diagnosed tumors in humans. Although a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and thus a topic of extensive ongoing clinical research. Consequently, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for medical oncologists, radiation oncologists, urologists and other healthcare providers who treat the disease. These proceedings from an interactive CME symposium held during the 2012 Genitourinary Cancers Symposium will offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.


    • Efficiently identify and educate patients with skeletal metastases about the efficacy and safety of available and emerging systemic bone-directed treatments.
    • Discriminate the clinically relevant differences between androgen-insensitive and castration-resistant metastatic prostate cancer as they relate to the integration of secondary hormonal agents into the treatment algorithm.
    • Recall recently reported and ongoing clinical trials attempting to optimize the effective delivery of chemotherapy to patients with prostate cancer.
    • Apply evidence-based research findings in the determination of best-practice sequencing of systemic therapies for patients with metastatic prostate cancer.
    • Explore the emerging data and active research evaluating novel agents in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
    • Counsel appropriately selected patients with biochemically recurrent, asymptomatic and symptomatic metastatic prostate cancer about availability of and participation in ongoing clinical trials.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers12/CME.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tomasz M Beer, MD
    Grover C Bagby Endowed Chair for Prostate Cancer Research
    Professor of Medicine, Hematology and Medical Oncology
    Deputy Director, OHSU Knight Cancer Institute
    Portland, Oregon

    Consulting Agreements: Dendreon Corporation, GTx Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cell Therapeutics Inc, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc; Speakers Bureau: Sanofi.

    Christopher J Logothetis, MD

    Genitourinary Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research, The Tisch Cancer Institute
    New York, New York

    Consulting Agreements: Amgen Inc, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Medivation Inc, Pfizer Inc, Sanofi.

    A Oliver Sartor, MD

    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Sanofi; Clinical Investigator: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Algeta ASA, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi, Teva Pharmaceuticals.

    Mary-Ellen Taplin, MD

    Associate Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Johnson & Johnson Pharmaceuticals, Medivation Inc, Sanofi; Paid Research: Genentech BioOncology, Novartis Pharmaceuticals Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2012
    Expiration date: April 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):
Introduction: Dr Love
Module 1:
Dr Sartor
Bone-Targeting Agents and Strategies
Module 2:
Dr Logothesis
Molecular Endocrinology of PC
Module 3:
Dr Beer
Novel Endocrine Agents
Module 4:
Dr Taplin
New Chemotherapeutic Agents and Strategies
Module 5:
Dr Oh
Sequencing of Systemic Treatment